Comparison Overview
Pharmacyclics, an AbbVie Company

Pharmacyclics, an AbbVie Company
999 East Arques Avenue, Sunnyvale, 94085, US
Last Update: 03/04/2026
Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), ...

Intas Pharmaceuticals
Sarkhej Gandhinagar Highway, Near Sola Bridge, Ahmedabad, Gujarat, IN
Last Update: 01/04/2026
Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of su...
Compliance Ranges Comparison

Pharmacyclics, an AbbVie Company







Intas Pharmaceuticals






Benchmark & Cyber Underwriting Signals
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Pharmacyclics, an AbbVie Company in 2026.
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Intas Pharmaceuticals in 2026.
Incident History - Pharmacyclics, an AbbVie Company (X = Date, Y = Severity)
Pharmacyclics, an AbbVie Company cyber incidents detection timeline including parent company and subsidiaries.
Incident History - Intas Pharmaceuticals (X = Date, Y = Severity)
Intas Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents

Pharmacyclics, an AbbVie Company

Intas Pharmaceuticals
FAQ
Latest Global CVEs
PraisonAI before 1.5.115 contains a path traversal vulnerability in MultiAgentMonitor that fails to sanitize agent IDs when building file paths. Attackers can include traversal sequences like ../ in agent IDs to read, write, or overwrite arbitrary files, enabling sensitive disclosure, denial of service, or code execution.
PraisonAI before 1.5.115 contains an information disclosure vulnerability in the MultiAgentLedger component that allows attackers to access sensitive data by registering agents with duplicate IDs. Attackers can exploit the lack of agent ID uniqueness enforcement to share ledger instances and expose system prompts and conversation history between agents.
PraisonAI before 1.5.128 contains a cross-origin agent execution vulnerability in the AGUI endpoint that allows remote attackers to trigger arbitrary agent execution. The POST /agui endpoint lacks authentication and hardcodes Access-Control-Allow-Origin: * headers, combined with Starlette's Content-Type-agnostic JSON parsing, enabling attackers to bypass CORS preflight checks via simple requests and exfiltrate sensitive agent responses including tool execution results and environment data.
PraisonAI before 4.5.128 contains an arbitrary shell command execution vulnerability where the UI modules hardcode approval_mode to auto, overriding administrator configuration from PRAISON_APPROVAL_MODE environment variable. Authenticated attackers can instruct the LLM agent to execute arbitrary shell commands via subprocess.run with shell=True, bypassing the manual approval gate and insufficient command sanitization blocklists.
PraisonAI before 1.5.128 caches tool approval decisions by tool name only, not by invocation arguments, allowing subsequent execute_command calls to bypass approval prompts. Attackers can exploit this by obtaining initial approval for a benign command, then silently exfiltrate API keys and credentials via subsequent shell commands without user consent.